Want more tips and tricks for reaching your health goals? Join Lark!

Take our 2-minute survey to find out if you’re eligible to join Lark which includes a smart scale and the chance to earn a Fitbit®.
Start now
*Terms and conditions apply
Close icon
< Back to Resource Center
< Back to Member Blog

How Digital Health Companies Can Get GLP-1s Right

Antall, MD, Chief Medical Officer, Lark Health
October 4, 2023
How Digital Health Companies Can Get GLP-1s Right

Are you at risk of prediabetes?

Lark can help lower your risk for Type 2 Diabetes through healthy habit formation, and data tracking.
Height: 5 ft 4 in
4' 0"
7' 0"
Weight: 160 lbs
90 lbs
500 lbs
Risk Level
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

What could 15% weight loss mean for you?

Feel more energetic and significantly reduce your risk of chronic conditions like diabetes and cardiovascular disease.

By clicking the button above, you agree to the Lark Terms & Conditions, Privacy Policy, and SMS Terms.

Current Weight: 250 lbs
120 lbs
500 lbs
Your weight loss could be*
- - lbs
Your new weight: -- lbs
Am I eligible?

By clicking the button above, you agree to the Lark Terms & Conditions, Privacy Policy, and SMS Terms.

*Results may vary. Based on the average weight loss in three, 68-week clinical trials of patients without diabetes who reached and maintained a dose of 2.4mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity. View study here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

I’ve worked in digital health for a long time and am constantly amazed at how innovators take on some of health care’s greatest challenges —  everything from removing barriers to care to new therapies that help people better manage conditions. 

Right now, however, I’m seeing that many in digital health are incorrectly approaching the opportunity to address one of the most significant public health crises we have ever faced —  the obesity and metabolic disease epidemic in the U.S.  New and highly promising GLP-1 medications (like Ozempic) could be game changers, but in the scramble to get these treatments to as many people as possible, many in digital health are missing the big  picture —  these medications are simply not the best treatment for everyone. The first priority should be getting these medications to the right people —  not just the most people —  and helping them succeed.  

GLP-1 drugs are costly — often costing1 $1,000 per month or more —  and difficult for many people to take successfully. One analysis2 found that 68 percent of patients starting GLP-1s for weight loss were no longer taking the medication after one year, and as many as 50% stop these medications in the first month. Ultimately, they are just not the right solution for everyone. And treating them as a one-size-fits-all solution, or the silver bullet for obesity, could result in massive costs for health plans, employers, and ultimately for consumers —  with few results to show for it. (A recent Business Group of Health survey3 found that 85% of employers reported concern around the long-term cost implications of GLP-1s and other weight management medications.)_

Instead of looking at this as a one-size-fits-all approach, we need to be focused on getting these drugs to the people who need them most, while offering others weight management solutions tailored to their needs. 

To start, the digital health community needs to focus our attention on the patients who need these treatments the most. 

A recent New York Times piece examined how in New York City, GLP-1 medications are primarily going to the city’s wealthiest zip codes4. We know that it is not a hotspot for metabolic diseases. It doesn’t help to expand access to these drugs if they are not getting to the people who would benefit most. But it happens because, as it stands,  the current GLP-1 clinical guidelines are quite permissive. In addition to including people with a BMI of 30 and over or with a BMI of 27 and over and a comorbid condition. By that definition, even I qualify for a GLP-1. And if everyone like me who was eligible under these guidelines were given these drugs, it would send our healthcare system into financial collapse. 

Instead, digital health companies must focus on responsible prescribing and to balance the clinical indications with the financial considerations. This includes working with skilled clinicians who have extensive experience in obesity management to fully qualify, screen, and support potential GLP-1 patients. 

Responsible prescribing is just the beginning. 

The next step is to supplement GLP-1s with focused clinical monitoring, education and dedicated support to encourage behavior change. Offering these services are particularly important, since GLP-1s alone won’t lead to long-term success. Patients need proper nutrition, activity, and continued guidance to ensure that they stay on these medications, remain healthy while taking them, and sustain weight loss once off of them. Digital health companies have the technological expertise and capabilities to make this happen, and to happen at scale, which is critical as we deploy GLP-1s to more of the population. 

Lastly, we can’t abandon those who are not good candidates for GLP-1s either.

We also need to be spending similar efforts on deploying weight management tools that are better suited for those who cannot tolerate GLP-1s or are not good candidates for the drug. That’s another place where digital health solutions are well-equipped to fill in the gaps. For example, app-guided therapy may be just as effective in helping patients adhere to their GLP-1 regimens as it can be for engaging patients who are not taking these medications. This type of coaching has already been shown to help patients lose weight and simultaneously improve chronic conditions like diabetes and heart disease through nutritional and activity counseling, and promoting healthy behaviors. 

It’s clear that GLP-1 medications are a game-changer in our efforts to address the obesity epidemic and that digital health solutions can play a significant role in augmenting the effects of these treatments. But digital health companies need to think critically about our role in supporting patients. We have a unique opportunity to make a difference, but we need to do it the right way. 




4 https://www.nytimes.com/2023/08/26/nyregion/ozempic-nyc-neighborhoods-diabetes.html

About Lark

Lark helps you eat better, move more, stress less, and improve your overall wellness. Lark’s digital coach is available 24/7 on your smartphone to give you personalized tips, recommendations, and motivation to lose weight and prevent chronic conditions like diabetes.

Read more

Get healthier with Lark & earn a Fitbit®

Lose weight, get more active, and eat better.
take 1-minute survey

See if Ozempic® is covered by insurance

Curb cravings and reach your weight loss goals!

Similar posts

GLP-1s Are Only One Part of The Obesity PuzzleGLP-1s Are Only One Part of The Obesity Puzzle

GLP-1s Are Only One Part of The Obesity Puzzle

GLP-1s Are Only One Part of The Obesity Puzzle

Learn more
3 Tips for Employers To Manage High Costs of GLP-1s3 Tips for Employers To Manage High Costs of GLP-1s

3 Tips for Employers To Manage High Costs of GLP-1s

3 Tips for Employers To Manage High Costs of GLP-1s

Learn more
Doctor TextingDoctor Texting

Weight Loss Drug Demand Must Be Addressed With New Solutions & Strategies

As the demand for GLP-1 medications continues to soar, health plans and employers must develop a weight management strategy that balances the clinical indications with the financial implications.

Learn more